Skip to main content
Top
Published in: Clinical and Translational Oncology 9/2010

01-09-2010 | News and Views

Institutional declaration in favour of the development of interdisciplinary cancer care in Spain

Authors: J. M. Borràs, Spanish Association of Surgeons, Federation of Spanish Oncology Societies, Spanish Society of Pathology, Spanish Society of Palliative Care, Spanish Society of Oncology Nursing, Spanish Society of Haematology and Haemotherapy, Spanish Society of Paediatric Haematology and Oncology, Spanish Society of Family and Community Medicine, Spanish Society of Nuclear Medicine and Molecular Imaging, Spanish Society of Primary Care Physicians, Spanish Society of Medical Oncology, Spanish Society of Radiation Oncology, Spanish Society of Psycho-Oncology, Spanish Society of Medical Radiology, Spanish Society of Mastology and Breast Pathology

Published in: Clinical and Translational Oncology | Issue 9/2010

Login to get access
Metadata
Title
Institutional declaration in favour of the development of interdisciplinary cancer care in Spain
Authors
J. M. Borràs
Spanish Association of Surgeons
Federation of Spanish Oncology Societies
Spanish Society of Pathology
Spanish Society of Palliative Care
Spanish Society of Oncology Nursing
Spanish Society of Haematology and Haemotherapy
Spanish Society of Paediatric Haematology and Oncology
Spanish Society of Family and Community Medicine
Spanish Society of Nuclear Medicine and Molecular Imaging
Spanish Society of Primary Care Physicians
Spanish Society of Medical Oncology
Spanish Society of Radiation Oncology
Spanish Society of Psycho-Oncology
Spanish Society of Medical Radiology
Spanish Society of Mastology and Breast Pathology
Publication date
01-09-2010
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 9/2010
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-010-0562-0

Other articles of this Issue 9/2010

Clinical and Translational Oncology 9/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine